Results of a six-year study found Hoya’s MiyoSmart spectacle lens continued to slow down the progression of myopia in children aged eight to 13.
The study also confirmed that children who stopped wearing the lens showed no rebound effect when compared to the initial rates of progression during the two-year randomised control trial or with the general population.
Natalia Vlasak, global head of medical and scientific affairs at Hoya Vision Care, said: ‘This six-year follow-up clinical study on the MiyoSmart spectacle lens, the longest study conducted on a myopia management spectacle lens ever, shows the myopia control effects are sustainable over time which is very exciting news.’
The findings were shared during the Association for Research in Vision and Ophthalmology (Arvo) 2022 in Colorado, US on May 1-7 by Professor Carly Lam from the Centre for Myopia Research at the Hong Kong Polytechnic University.